Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults (MEDI8852)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02350751
Recruitment Status : Completed
First Posted : January 30, 2015
Last Update Posted : July 13, 2015
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC

Brief Summary:
The purpose of this study is to evaluate the safety and pharmacokinetics of MEDI8852 compared to placebo when administered to healthy adult subjects.

Condition or disease Intervention/treatment Phase
Influenza Drug: MEDI8852 Drug: Placebo Phase 1

Detailed Description:
This is a phase 1, single-dose, double-blind, placebo-controlled, dose-escalation study to evaluate the safety and pharmacokinetics of MEDI8852 compared to placebo when administered to healthy adult subjects. Approximately 40 subjects will be entered to receive treatment across 4 fixed dose cohorts at 1 site. Investigational product will be delivered intravenously (IV). A total of 4 different dose levels of investigational product will be evaluated across the cohorts. Subjects will be followed for approximately 100 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1 Double-blind, Single-dose, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Healthy Adults
Study Start Date : January 2015
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: MEDI8852
MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) supplied as 50 mg/mL solution for infusion. MEDI8852 is being evaluated for treatment of patients hospitalized with influenza A.
Drug: MEDI8852
Placebo Comparator: Placebo
Solution containing no active ingredients
Drug: Placebo



Primary Outcome Measures :
  1. Number of Participants with Adverse Events as a Measure of Safety and tolerability of MEDI8852 [ Time Frame: 100 days postdose ]
    Occurrence of adverse events, serious adverse events, adverse events of special interest, and new onset chronic disease.

  2. Number of Participants with Adverse Events as a Measure of Safety and tolerability of MEDI8852 [ Time Frame: 28 days postdose ]
    Clinical laboratory assessments (ie, serum chemistry, hematology, and urinalysis)


Secondary Outcome Measures :
  1. Pharmacokinetics of MEDI8852 in serum: terminal-phase elimination (t½) [ Time Frame: 100 days postdose ]
    This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.

  2. Pharmacokinetics of MEDI8852 in serum: systemic clearance (CL) [ Time Frame: 100 days postdose ]
    This variable will be estimated for MEDI8852 in the IV cohorts where the data allows.

  3. Pharmacokinetics of MEDI8852 in serum: time to maximum serum concentration (Cmax) [ Time Frame: 100 days postdose ]
    This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.

  4. Pharmacokinetics of MEDI8852 in serum: area under the concentration time curve from 0 to t (AUC 0-t) and from 0 to infinity (AUC 0-inf) [ Time Frame: 100 days postdose ]
    This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.

  5. Incidence of anti-drug antibody to MEDI8852 in serum [ Time Frame: 100 days postdose ]
    This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.

  6. Pharmacokinetics of MEDI8852 in serum:volume at steady state (Vss) [ Time Frame: 100 days postdose ]
    This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age 18 through 65 years at the time of screening
  2. Weight ≥ 45 kg and ≤ 110 kg at screening
  3. Healthy by medical history, physical examination, and baseline safety laboratory studies.
  4. Systolic blood pressure (BP) < 140 mm Hg and diastolic BP < 90 mm Hg at screening
  5. Electrocardiogram without clinically significant abnormalities at screening
  6. Able to complete the follow-up period through Day 101 as required by the protocol
  7. Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for at least 28 days prior to the first dose of investigational product and must agree to continue using such precautions through Day 101 of the study

Exclusion Criteria:

  1. Acute illness, including fever > 99.5°F, on day prior to or day of planned dosing
  2. Any drug therapy within 7 days prior to Day 1 (except contraceptives or a single use of acetaminophen, aspirin, antihistamine. and other nutritional supplements that have not been taken for at least 30 days prior to enrollment, are not exclusionary.
  3. Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 2 months prior to screening
  4. Receipt of immunoglobulin or blood products within 6 months prior to screening
  5. Receipt of any vaccine within 14 days prior to investigational product dosing or planned receipt of any influenza vaccine within 100 days after investigational product dosing
  6. Either history of active infection with hepatitis B or C or positive test for hepatitis C or for hepatitis B surface antigen at screening
  7. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or serum creatinine above the upper limit of normal or hemoglobin, white blood cell count, or platelet count below the lower limit of normal at screening
  8. History of malignancy other than treated non-melanoma skin cancers or locally-treated cervical cancer in previous 5 years
  9. Pregnant or nursing mother
  10. History of alcohol or drug abuse within the past 2 years tha OR positive Class A drug screen for amphetamines, barbiturates, opiates, or cocaine at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02350751


Locations
Layout table for location information
United States, Kansas
Research Site
Overland Park, Kansas, United States
Sponsors and Collaborators
MedImmune LLC

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT02350751     History of Changes
Other Study ID Numbers: D6000C00001
First Posted: January 30, 2015    Key Record Dates
Last Update Posted: July 13, 2015
Last Verified: July 2015

Keywords provided by MedImmune LLC:
Influenza, Flu, Flu A, Influenza A

Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
MEDI8852
Antiviral Agents
Anti-Infective Agents